Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.
Journal: Human vaccines & immunotherapeutics
Published: January 13, 2025
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial.
Journal: Human vaccines & immunotherapeutics
Published: May 04, 2023
Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
Journal: Vaccine
Published: March 09, 2022
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
Journal: The Journal of infectious diseases
Published: February 22, 2019
An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults.
Journal: The Journal of infectious diseases
Published: July 11, 2018
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.
Journal: The Journal of infectious diseases
Published: August 15, 2017
B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
Journal: Clinical and vaccine immunology : CVI
Published: December 27, 2016
Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
Journal: The Journal of infectious diseases
Published: November 25, 2016
Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
Journal: The Journal of infectious diseases
Published: March 28, 2016
Serological Correlates of Protection against a GII.4 Norovirus.
Journal: Clinical and vaccine immunology : CVI
Published: March 31, 2015
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
Journal: The Journal of infectious diseases
Published: September 12, 2014
Last Updated: 09/26/2026